Clinical Trial Detail

NCT ID NCT02870920
Title Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Canadian Cancer Trials Group
Indications

colorectal cancer

Therapies

Durvalumab + Tremelimumab

Age Groups: adult senior

No variant requirements are available.